Valneva is advancing toward U.S. FDA accelerated approval of the France-based biologics company’s VLA1553 after the specialty vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease, in a published analysis of Phase III results.
Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
An outbreak of dengue fever is suspected of killing dozens of people in India’s northern state of Uttar Pradesh since the start of September, and authorities launched a campaign to destroy mosquito breeding grounds.
French specialty vaccine maker Valneva shared positive topline results from ongoing trials for a potential single-shot vaccine against chikungunya.
Valneva SE was awarded Breakthrough Therapy Designation for the company’s single-shot chikungunya vaccine candidate, VLA1553, by the U.S. Food and Drug Administration.
After months of bad news regarding Covid-19 vaccine manufacturing issues, Emergent BioSolutions posted positive two-year data related to the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate.
Takeda has touted the potential of the company’s Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.
Genetically modified mosquitoes were released for the first time in the United States, taking flight in the Florida Keys in a pilot program intended to reduce the spread of deadly diseases such as dengue, yellow fever and the Zika virus.
A new study that analyzed the coronavirus outbreak in Brazil found a link between the spread of the virus and past outbreaks of dengue fever that suggests exposure to the mosquito-transmitted illness may provide some level of immunity against Covid-19.
Takeda Pharmaceutical Co.’s experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but TAK-003 failed to protect against one type of the virus in people with no prior exposure to dengue.